| pubmed-article:21134693 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21134693 | lifeskim:mentions | umls-concept:C0015967 | lld:lifeskim |
| pubmed-article:21134693 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:21134693 | lifeskim:mentions | umls-concept:C0026764 | lld:lifeskim |
| pubmed-article:21134693 | lifeskim:mentions | umls-concept:C0218640 | lld:lifeskim |
| pubmed-article:21134693 | lifeskim:mentions | umls-concept:C0210630 | lld:lifeskim |
| pubmed-article:21134693 | lifeskim:mentions | umls-concept:C0332189 | lld:lifeskim |
| pubmed-article:21134693 | lifeskim:mentions | umls-concept:C0392756 | lld:lifeskim |
| pubmed-article:21134693 | lifeskim:mentions | umls-concept:C1707455 | lld:lifeskim |
| pubmed-article:21134693 | lifeskim:mentions | umls-concept:C0524864 | lld:lifeskim |
| pubmed-article:21134693 | lifeskim:mentions | umls-concept:C0021149 | lld:lifeskim |
| pubmed-article:21134693 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:21134693 | pubmed:dateCreated | 2011-6-13 | lld:pubmed |
| pubmed-article:21134693 | pubmed:abstractText | The aim of this study was to show a lower incidence of febrile episodes in multiple myeloma patients receiving lenograstim vs. filgrastim after high-dose cyclophosphamide for stem cell mobilization. Patients treated with cyclophosphamide were randomly assigned to receive filgrastim or lenograstim. Primary endpoint was the incidence of febrile episodes. 5.1% patients developed a febrile episode, 9.1% with filgrastim and 1.1% with lenograstim. Lenograstim group presented a significantly higher absolute CD34+ cell number compared with the filgrastim group but no differences were detected for collection efficacy. The study demonstrated a lower incidence of febrile episodes with lenograstim compared to filgrastim. | lld:pubmed |
| pubmed-article:21134693 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21134693 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21134693 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21134693 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21134693 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21134693 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21134693 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21134693 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21134693 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21134693 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21134693 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21134693 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:21134693 | pubmed:issn | 1873-5835 | lld:pubmed |
| pubmed-article:21134693 | pubmed:author | pubmed-author:PetriniMarioM | lld:pubmed |
| pubmed-article:21134693 | pubmed:author | pubmed-author:MiloneGiusepp... | lld:pubmed |
| pubmed-article:21134693 | pubmed:author | pubmed-author:SpecchiaGiorg... | lld:pubmed |
| pubmed-article:21134693 | pubmed:author | pubmed-author:PastoreDomeni... | lld:pubmed |
| pubmed-article:21134693 | pubmed:author | pubmed-author:Di... | lld:pubmed |
| pubmed-article:21134693 | pubmed:author | pubmed-author:MazzaPatrizio... | lld:pubmed |
| pubmed-article:21134693 | pubmed:author | pubmed-author:OrciuoloEnric... | lld:pubmed |
| pubmed-article:21134693 | pubmed:author | pubmed-author:CangialosiClo... | lld:pubmed |
| pubmed-article:21134693 | pubmed:author | pubmed-author:BudaGabrieleG | lld:pubmed |
| pubmed-article:21134693 | pubmed:author | pubmed-author:PietrantuonoG... | lld:pubmed |
| pubmed-article:21134693 | pubmed:author | pubmed-author:MauroElisaE | lld:pubmed |
| pubmed-article:21134693 | pubmed:author | pubmed-author:MarturanoEmer... | lld:pubmed |
| pubmed-article:21134693 | pubmed:author | pubmed-author:De... | lld:pubmed |
| pubmed-article:21134693 | pubmed:copyrightInfo | Copyright © 2010 Elsevier Ltd. All rights reserved. | lld:pubmed |
| pubmed-article:21134693 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21134693 | pubmed:volume | 35 | lld:pubmed |
| pubmed-article:21134693 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21134693 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21134693 | pubmed:pagination | 899-903 | lld:pubmed |
| pubmed-article:21134693 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:21134693 | pubmed:meshHeading | pubmed-meshheading:21134693... | lld:pubmed |
| pubmed-article:21134693 | pubmed:meshHeading | pubmed-meshheading:21134693... | lld:pubmed |
| pubmed-article:21134693 | pubmed:meshHeading | pubmed-meshheading:21134693... | lld:pubmed |
| pubmed-article:21134693 | pubmed:meshHeading | pubmed-meshheading:21134693... | lld:pubmed |
| pubmed-article:21134693 | pubmed:meshHeading | pubmed-meshheading:21134693... | lld:pubmed |
| pubmed-article:21134693 | pubmed:meshHeading | pubmed-meshheading:21134693... | lld:pubmed |
| pubmed-article:21134693 | pubmed:meshHeading | pubmed-meshheading:21134693... | lld:pubmed |
| pubmed-article:21134693 | pubmed:meshHeading | pubmed-meshheading:21134693... | lld:pubmed |
| pubmed-article:21134693 | pubmed:meshHeading | pubmed-meshheading:21134693... | lld:pubmed |
| pubmed-article:21134693 | pubmed:meshHeading | pubmed-meshheading:21134693... | lld:pubmed |
| pubmed-article:21134693 | pubmed:meshHeading | pubmed-meshheading:21134693... | lld:pubmed |
| pubmed-article:21134693 | pubmed:meshHeading | pubmed-meshheading:21134693... | lld:pubmed |
| pubmed-article:21134693 | pubmed:meshHeading | pubmed-meshheading:21134693... | lld:pubmed |
| pubmed-article:21134693 | pubmed:meshHeading | pubmed-meshheading:21134693... | lld:pubmed |
| pubmed-article:21134693 | pubmed:meshHeading | pubmed-meshheading:21134693... | lld:pubmed |
| pubmed-article:21134693 | pubmed:meshHeading | pubmed-meshheading:21134693... | lld:pubmed |
| pubmed-article:21134693 | pubmed:meshHeading | pubmed-meshheading:21134693... | lld:pubmed |
| pubmed-article:21134693 | pubmed:meshHeading | pubmed-meshheading:21134693... | lld:pubmed |
| pubmed-article:21134693 | pubmed:meshHeading | pubmed-meshheading:21134693... | lld:pubmed |
| pubmed-article:21134693 | pubmed:meshHeading | pubmed-meshheading:21134693... | lld:pubmed |
| pubmed-article:21134693 | pubmed:meshHeading | pubmed-meshheading:21134693... | lld:pubmed |
| pubmed-article:21134693 | pubmed:meshHeading | pubmed-meshheading:21134693... | lld:pubmed |
| pubmed-article:21134693 | pubmed:meshHeading | pubmed-meshheading:21134693... | lld:pubmed |
| pubmed-article:21134693 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21134693 | pubmed:articleTitle | Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization. | lld:pubmed |
| pubmed-article:21134693 | pubmed:affiliation | Department of Oncology, Transplants and Advanced Technologies, University of Pisa, Pisa, Italy. orci@sssup.it | lld:pubmed |
| pubmed-article:21134693 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21134693 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:21134693 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:21134693 | pubmed:publicationType | Multicenter Study | lld:pubmed |
